Timing of anticoagulation for preventing blood clots in patients with brain hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of different timing for anticoagulation therapy using heparin to prevent venous thromboembolism in patients suffering from hypertensive intracerebral hemorrhage. Participants will be randomly assigned to receive anticoagulation either early, within the first two days after admission, or delayed, starting on the third day. The study aims to determine which timing minimizes the risk of bleeding complications while effectively preventing blood clots. The outcomes will help establish optimal guidelines for anticoagulation in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* the presence of hypertensive intracerebral hemorrhage

Exclusion Criteria:

* Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)
* Being on an anticoagulant during preadmission period and on day of hospital admission
* Death within the first 2 days after hospital admission
* Detection of venous thromboembolism in a patient at the moment of hospital admission
* Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin
* The presence of a malignancy (cancer) in a patient at the moment of hospital admission

Where it's running

• Moscow City Clinical Hospital named after V.M. Buyanov
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Alexander Pryamikov, MD, PhD, Associate Professor
• Email: pryamikov80@rambler.ru
• Phone: +7 (903) 286-25-52

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized blood thinner treatment for hip and knee replacement patients

  This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.

  Recruiting at 12 sites Phase 4 Leiden University Medical Center · Apeldoorn, Gelderland and 12 other locations · NCT06581965

• Evaluating a new decision support tool for diagnosing blood clots

  This study is testing a new tool to help doctors diagnose blood clots in patients who might have conditions like pulmonary embolism or deep vein thrombosis, using fresh blood samples.

  Recruiting at 4 sites Diagnostica Stago R&D · Niort, Sartres and 3 other locations · NCT06480994

• Comparing rivaroxaban and low-molecular weight heparin for preventing blood clots in patients with lower limb trauma

  This study is testing if a new blood thinner called rivaroxaban can prevent blood clots better than a standard treatment in patients with leg injuries who are at high risk for clots.

  Recruiting at 26 sites Phase 3 University Hospital, Angers · Agen and 36 other locations · NCT06195540

• Study on the safety and performance of Celect Platinum Vena Cava Filters

  This study is testing how safe and effective the Celect Platinum Vena Cava Filters are for patients over time after they've had them placed in their bodies.

  Recruiting at 7 sites Cook Group Incorporated · Los Angeles, California and 6 other locations · NCT05881798

• Using geko device to prevent blood clots in stroke patients

  This study is testing if the geko™ device can help prevent blood clots in stroke patients who can’t move around, compared to the standard treatment they usually get.

  Recruiting at 17 sites Firstkind Ltd · Bury St Edmunds, Suffolk and 17 other locations · NCT05476913

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.